Literature DB >> 22345297

Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness.

Lucieli Ceolin1, Débora Rodrigues Siqueira, Carla Vaz Ferreira, Mírian Romitti, Silvana Cavalcante Maia, Leonardo Leiria, Daisy Crispim, Patrícia Ashton-Prolla, Patrícia Ashton Prolla, Ana Luiza Maia.   

Abstract

OBJECTIVE: RET single nucleotide polymorphisms (SNPs) have been implicated in the pathogenesis and progression of medullary thyroid carcinoma (MTC). Here, we investigated the influence of multiple RET variants (G691S, L769L, S836S, and S904S) on the risk of MTC and tumor behavior. DESIGN AND METHODS: One hundred and seven MTC patients and 308 cancer-unaffected control individuals were included. SNPs were analyzed using Custom TaqMan Genotyping Assays. Haplotypes based on the combination of allelic variants were inferred using a Bayesian statistical method.
RESULTS: The minor allele frequencies in MTC patients were as follows: L769L: 28.0%, S836S: 8.9%, and G691S/S904S: 22.2%. The RET L769L and S836S SNPs were associated with increased risk of MTC (odds ratio (OR)=1.95, 95% CI: 1.2-3.1, P=0.005 and OR=2.29, 95% CI: 1.2-4.5, P=0.017 respectively). The adjusted OR for individuals harboring haplotypes with three or more polymorphic alleles was 3.79 (95% CI: 1.5-9.5; P=0.004), indicating an additive effect of these variants on the risk for MTC. Among MTC patients, no significant associations were observed between RET variants and age of diagnosis or tumor size but serum calcitonin levels increased according to the number of risk alleles (P=0.003). Remarkably, patients carrying haplotypes with three or four risk alleles had increased risk for lymph node and distant metastases at diagnosis (OR=5.84, 95% CI: 1.1-31.2, P=0.039). Further analysis using Kaplan-Meier model demonstrated that metastatic disease occurred earlier in individuals harboring multiple risk alleles.
CONCLUSION: Our results demonstrated an additive effect of RET polymorphic alleles on the estimated risk of developing aggressive MTC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22345297     DOI: 10.1530/EJE-11-1060

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  16 in total

1.  Quantitative assessment of the association between L769L and S836S polymorphisms at RET gene and medullary thyroid carcinoma risk.

Authors:  Yuanqi Zhang; Sanming Wang; Xiaodong Chen; Shengchao Huang; Jianwen Li
Journal:  Tumour Biol       Date:  2014-04-04

Review 2.  Molecular genetics of thyroid cancer.

Authors:  Maha Rebaї; Ahmed Rebaї
Journal:  Genet Res (Camb)       Date:  2016-05-13       Impact factor: 1.588

3.  Kinome sequencing reveals RET G691S polymorphism in human neuroendocrine lung cancer cell lines.

Authors:  Nadiya Sosonkina; Seung-Keun Hong; Dmytro Starenki; Jong-In Park
Journal:  Genes Genomics       Date:  2014-12       Impact factor: 1.839

4.  RET polymorphisms might be the risk factors for thyroid cancer.

Authors:  Rui-Xue Huang; Fei Yang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

5.  Genetic diagnosis of a Chinese multiple endocrine neoplasia type 2A family through whole genome sequencing.

Authors:  Zhen-Fang DU; Peng-Fei Li; Jian-Qiang Zhao; Zhi-Lie Cao; Feng Li; Ju-Ming Ma; Xiao-Ping Qi
Journal:  J Biosci       Date:  2017-06       Impact factor: 1.826

6.  Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency.

Authors:  Sara Milićević; Damijan Bergant; Tina Žagar; Barbara Perić
Journal:  Croat Med J       Date:  2021-04-30       Impact factor: 1.351

7.  Haplotype Frequency of G691S/S904S in the RET Proto-Onco-gene in Patients with Medullary Thyroid Carcinoma.

Authors:  Sara Sheikholeslami; Marjan Zarif Yeganeh; Laleh Hoghooghi Rad; Hoda Golab Ghadaksaz; Mehdi Hedayati
Journal:  Iran J Public Health       Date:  2014-02       Impact factor: 1.429

8.  Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paraganglioma.

Authors:  Joakim Crona; Alberto Delgado Verdugo; Dan Granberg; Staffan Welin; Peter Stålberg; Per Hellman; Peyman Björklund
Journal:  Endocr Connect       Date:  2013-05-28       Impact factor: 3.335

9.  Efficacy and tolerability of pharmacotherapy options for the treatment of medullary thyroid cancer.

Authors:  H A Deshpande; K Sheth; J A Sosa; S Roman
Journal:  Clin Med Insights Oncol       Date:  2012-10-31

Review 10.  A differential diagnosis of inherited endocrine tumors and their tumor counterparts.

Authors:  Sergio P A Toledo; Delmar M Lourenço; Rodrigo A Toledo
Journal:  Clinics (Sao Paulo)       Date:  2013-07       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.